Lumvoa Broke Tepezza’s Monopoly. Now Viridian Must Prove It Can Sell

Lumvoa Broke Tepezza’s Monopoly. Now Viridian Must Prove It Can Sell.

Viridian entered a $1.9 billion market at price parity with a shorter infusion course and a broader label. Two months earlier, Amgen had already reported Phase 3 data for a subcutaneous Tepezza. The axis Viridian is competing on was closing before it opened.

On Friday 26 June 2026, the FDA approved Lumvoa (veligrotug-vvze) for thyroid eye disease. Viridian Therapeutics announced it the following Monday and said the product would launch immediately — its first commercial product, and the first competitor Amgen’s Tepezza has faced since it created the category in 2020.

Tepezza generated $1.9 billion in 2025 as the only approved treatment for the disease. That is the monopoly Lumvoa broke.

The commercial framing that dominated the coverage was treatment burden: Lumvoa is five infusions every three weeks, against Tepezza’s eight. Viridian priced at parity — around $150,000 for a course — rather than undercutting, and put the argument to payers as a shorter pathway at the same cost.

That framing has one problem. In April 2026, two months before Lumvoa was approved, Amgen reported Phase 3 results showing that a subcutaneous Tepezza delivered by on-body injector performs comparably to the intravenous version.

Viridian’s convenience advantage arrived with an expiry date already attached to it.

01 — The ApprovalWhat the FDA Actually Cleared

Lumvoa carried Breakthrough Therapy designation into approval. Its pivotal package is THRIVE in active disease, published in Ophthalmology, and THRIVE-2 in chronic disease, presented at the American Academy of Ophthalmology.

02 — The Real AssetThe Label, Not the Infusion Count

Most of the commentary led with five infusions against eight. That is the weakest of Viridian’s three advantages, and section four explains why.

The durable advantage is where Lumvoa can be positioned.

Tepezza’s label is primarily supported by data in active TED — the inflammatory phase. Lumvoa’s label includes both active and chronic disease. Chronic TED is the stable phase, where the inflammation has settled but patients can still live with persistent bulging, double vision, disfigurement and functional impairment.

That is not a marginal extension. It is a population that has largely been managed with surgery or watchful waiting because no drug label reached it.

03 — SafetyThe Ceiling Is Written Into the Label

IGF-1R inhibition is not a clean-risk mechanism, and the approved prescribing information says so with numbers rather than categories.

This is the constraint on the chronic-TED thesis, and it cuts precisely where the opportunity is.

For an active-disease patient with high inflammatory burden and threatened vision, the benefit-risk conversation is straightforward. For a chronic patient with stable but persistent symptoms, being asked to accept a risk of permanent hearing loss is a different discussion entirely — and it is the discussion Viridian’s biggest differentiator requires physicians to have.

Which means launch execution is not only about access. It is baseline audiometry, follow-up hearing monitoring, glucose monitoring, infusion-reaction management and patient selection discipline. In rare disease, monitoring logistics are part of the product, and a product can win on efficacy and still lose momentum if the monitoring burden feels heavy in clinic.

04 — The Closing WindowAmgen Was Already Answering the Convenience Argument

Here is the sequence, which almost no coverage assembled.

05 — The ContestSegmentation, Not Replacement

Viridian does not need to destroy Tepezza. It needs to make physicians segment.

That means converting the question from should I use Tepezza? to which patient gets Tepezza, which gets Lumvoa, and which waits for a subcutaneous option? Once a monopoly category becomes a segmented category, the incumbent loses automatic control of the treatment conversation — and that is a bigger change than any single prescription.

Price parity is the interesting choice here. Viridian did not enter with a discount provocation, which would have invited a rebate war it cannot win against Amgen’s contracting scale. It entered with a rational access argument: if cost is the same, why should every patient default into the longer incumbent pathway?

That does not guarantee coverage. It does mean payers cannot dismiss the product on price, which is the usual first line of defence.

06 — The Second GateViridian Is Now a Commercial Company

Approval retired one binary. It created another.

Before 26 June, Viridian was judged on trial readouts, regulatory probability and pipeline optionality. After it, the company is judged on payer coverage, benefit verification, prior-authorisation approval rates, infusion-centre onboarding, physician adoption, patient starts, abandonment and revenue conversion.

That is where biotech launches most often disappoint, and the sell side is already pricing it. William Blair, while arguing Lumvoa can capture meaningful share on its profile across both populations, warned investors to hold modest expectations for revenue in the second half of 2026 given the time required to process patients and secure reimbursement.

The company has done the visible preparation — coordination with providers, payers and advocacy groups, plus a patient support programme. None of that is the same as an operating commercial machine. Amgen has one; Viridian is building one while competing against it.

One capital note worth registering: Kissei has paid Viridian $70 million for Japanese rights, which partially funds the US launch without dilution. That is a small but real advantage over the usual first-launch financing squeeze — the position Zenas found itself in when its own Phase 3 succeeded and the market repriced it downward anyway.

07 — ScoringWitfire Risk Score

Scored for Viridian Therapeutics on the position created by approval.

Read the spread. Evidence Integrity 2.5 against Competitive Displacement 8.0 — the science is finished and everything left is commercial. That is an unusual shape, and it is why approval-day enthusiasm is the wrong signal to trade on.

08 — PositionInvestor Takeaway

VRDN (Nasdaq). Shares rose 13.8% to $20.36 pre-market on the announcement, which is a rational response to a binary being retired. The next leg depends on things no trial can answer: coverage decisions, prior-authorisation criteria, and whether specialists actually start treating chronic patients pharmacologically. Three questions decide the equity — can Lumvoa win chronic TED first, does the shorter course drive real adoption, and does elegrobart arrive before Amgen’s on-body injector makes it irrelevant. Only the first is fully within Viridian’s control.

AMGN. The threat is real and manageable. Tepezza keeps the brand, the installed base and the contracting scale, and Amgen has already reported the Phase 3 data that answers Viridian’s convenience argument. What it has lost is immunity from comparison — every Lumvoa prescription is evidence the category can split. The likely response is defensive rather than dramatic: real-world evidence, prescriber reinforcement, payer access protection, and pushing the subcutaneous programme.

The transferable read. When a challenger’s differentiation is on delivery rather than on data, check whether the incumbent is already building the same delivery. Here it was, and it reported two months before the challenger was even approved.

What to watch, in order

1. Chronic TED uptake specifically. Not total prescriptions — chronic ones. That is the only advantage an on-body injector cannot copy, and the only test of whether the broad label converts into behaviour.
2. Amgen’s regulatory timeline for subcutaneous Tepezza. The date this arrives is the date Viridian’s convenience argument ends. Everything in the bull case is scheduled against it.
3. First payer coverage decisions and prior-authorisation criteria. Whether Lumvoa is treated as equal, restricted or step-edited behind Tepezza decides how much of the label is actually reachable.
4. Hearing-monitoring protocols in practice. Physician comfort with audiometry logistics determines whether chronic patients get treated at all.
5. Elegrobart BLA submission in Q1 2027. Slippage here is more damaging than it looks, because the window is defined by someone else’s timeline.
6. Second-half 2026 revenue against modest expectations. The gap between approval excitement and commercial reality shows up here first.

09 — VerdictThe Category Stopped Being Uncontested

Lumvoa is not a symbolic approval and it is not a Tepezza killer. Viridian did not enter with a weak follower antibody — it entered with the broadest label in the category, rapid symptom improvement, and the first significant diplopia-resolution data in both disease stages. That is enough to make physicians, payers and Amgen reconsider how the category should be divided.

But the product shares the IGF-1R class burden, including a labelled risk of permanent hearing loss. It still requires infusion. And it is launching against an incumbent with six years of conditioning and a subcutaneous programme already through Phase 3.

So the correct reading is narrow. Before Lumvoa, thyroid eye disease was a Tepezza market. After Lumvoa, it is a segmentation market — active against chronic, five infusions against familiarity, diplopia data against real-world experience, intravenous today against subcutaneous tomorrow.

Viridian’s clearest wedge is chronic disease, where the label matters most and where persistent symptoms may finally become a pharmacological conversation rather than a surgical one. Its weakest is the infusion count, because the incumbent has already shown it can answer that.

The monopoly did not end overnight. What ended is Tepezza’s immunity from comparison. Whether that is worth $1.9 billion of anybody’s revenue depends on a salesforce Viridian has not yet had to run.